Where are we at?
We are at the hands of the FDA/TGA, now. Thanks Paul. Everyone is frustrated. Balance sheet is shot.
Paul (and Donna) either has supreme confidence in our data, is acting on the information at non binding agreement stages or is a complete fool. COMPLETE.
But if the regulators allow us to apply for the programs on offer (BT, AA, Provisional Approval) and our optimal dose is green lighted, we will re-rate if…… our cash position can change.
Matt and SW will (in my completely nativity) have 1 or 2 shots at obtaining a non dilutive funding and they should be able to achieve this.
Paul may redeem himself, hard to know
- Forums
- ASX - By Stock
- Where we at?
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
2.20%
!
46.5¢

Where are we at? We are at the hands of the FDA/TGA, now. Thanks...
-
-
- There are more pages in this discussion • 407 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
46.5¢ |
Change
0.010(2.20%) |
Mkt cap ! $184.8M |
Open | High | Low | Value | Volume |
45.5¢ | 48.0¢ | 44.0¢ | $534.2K | 1.168M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5245 | 45.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
47.0¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 23000 | 0.450 |
1 | 10000 | 0.440 |
1 | 23255 | 0.430 |
2 | 45000 | 0.425 |
2 | 21531 | 0.415 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 10000 | 1 |
0.475 | 13560 | 2 |
0.480 | 90598 | 3 |
0.485 | 10000 | 1 |
0.490 | 18000 | 2 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online